STOCK TITAN

InMode to Report Second Quarter 2025 Financial Results and Hold Conference Call on July 30, Expects Q2 Revenue Between $95.4M-$95.5M, Decreases Full Year 2025 Revenue Guidance to be Between $365M-$375M

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

InMode (NASDAQ: INMD), a leading medical technology provider, has announced preliminary Q2 2025 financial expectations and revised its full-year guidance. The company expects Q2 2025 revenue between $95.4-$95.5 million with a non-GAAP gross margin of 79-80%.

Due to market weakness and U.S. economic uncertainty, InMode has decreased its full-year 2025 revenue guidance to $365-375 million, down from the previous guidance of $395-405 million. The company will discuss detailed Q2 2025 results in a conference call scheduled for July 30, 2025.

InMode (NASDAQ: INMD), un importante fornitore di tecnologia medica, ha annunciato le aspettative preliminari per il secondo trimestre 2025 e ha rivisto le previsioni per l'intero anno. La società prevede un fatturato per il Q2 2025 compreso tra 95,4 e 95,5 milioni di dollari con un margine lordo non-GAAP del 79-80%.

A causa della debolezza del mercato e dell'incertezza economica negli Stati Uniti, InMode ha ridotto la stima del fatturato annuale 2025 a 365-375 milioni di dollari, rispetto alla precedente previsione di 395-405 milioni. La società discuterà i risultati dettagliati del Q2 2025 in una conference call prevista per il 30 luglio 2025.

InMode (NASDAQ: INMD), un proveedor líder en tecnología médica, ha anunciado las expectativas preliminares para el segundo trimestre de 2025 y ha revisado su guía para todo el año. La compañía espera unos ingresos en el Q2 2025 entre 95,4 y 95,5 millones de dólares con un margen bruto non-GAAP del 79-80%.

Debido a la debilidad del mercado y la incertidumbre económica en EE. UU., InMode ha reducido su guía de ingresos para todo el año 2025 a 365-375 millones de dólares, desde la guía anterior de 395-405 millones. La compañía discutirá los resultados detallados del Q2 2025 en una llamada programada para el 30 de julio de 2025.

InMode (NASDAQ: INMD)는 선도적인 의료 기술 제공업체로서 2025년 2분기 예비 실적 전망과 연간 가이던스 수정 내용을 발표했습니다. 회사는 2025년 2분기 매출을 9,540만~9,550만 달러로 예상하며, non-GAAP 기준 총이익률은 79~80%로 예상합니다.

시장 약세와 미국 경제 불확실성으로 인해 InMode는 2025년 연간 매출 가이던스를 기존 3억 9,500만~4억 500만 달러에서 3억 6,500만~3억 7,500만 달러로 하향 조정했습니다. 회사는 2025년 7월 30일 예정된 컨퍼런스 콜에서 2분기 상세 실적을 발표할 예정입니다.

InMode (NASDAQ : INMD), un fournisseur majeur de technologies médicales, a annoncé ses prévisions financières préliminaires pour le deuxième trimestre 2025 et a révisé ses prévisions annuelles. La société prévoit un chiffre d'affaires pour le T2 2025 compris entre 95,4 et 95,5 millions de dollars avec une marge brute non-GAAP de 79 à 80 %.

En raison de la faiblesse du marché et de l'incertitude économique aux États-Unis, InMode a réduit ses prévisions de chiffre d'affaires pour l'ensemble de l'année 2025 à 365-375 millions de dollars, contre une précédente estimation de 395-405 millions. La société présentera les résultats détaillés du T2 2025 lors d'une conférence téléphonique prévue le 30 juillet 2025.

InMode (NASDAQ: INMD), ein führender Anbieter von Medizintechnik, hat vorläufige Finanzerwartungen für das zweite Quartal 2025 bekanntgegeben und seine Jahresprognose angepasst. Das Unternehmen erwartet einen Umsatz im Q2 2025 zwischen 95,4 und 95,5 Millionen US-Dollar mit einer Non-GAAP-Bruttomarge von 79-80%.

Aufgrund von Marktschwäche und wirtschaftlicher Unsicherheit in den USA hat InMode seine Umsatzprognose für das Gesamtjahr 2025 auf 365-375 Millionen US-Dollar gesenkt, zuvor lag die Prognose bei 395-405 Millionen. Das Unternehmen wird die detaillierten Ergebnisse für Q2 2025 in einer Telefonkonferenz am 30. Juli 2025 erläutern.

Positive
  • Expected Q2 2025 non-GAAP gross margin of 79-80% shows strong profitability
  • Maintaining high-margin business model despite market challenges
Negative
  • Reduced full-year 2025 revenue guidance by approximately $30 million
  • Market weakness and economic uncertainty affecting business performance
  • Expected Q2 revenue indicates potential growth challenges

Conference call to be held on Wednesday, July 30, 2025, at 8:30 a.m. Eastern Time

YOKNEAM, Israel, July 10, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter 2025 before the Nasdaq market opens on Wednesday, July 30, 2025.

InMode Logo

InMode is currently finalizing its financial results for the second quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may arise between now and the time such financial results are finalized.

Due to continued market weakness and persistent uncertainty surrounding the U.S. economic outlook, management has decided to revise its full year guidance. Based on preliminary results, management expects:

  • Revenue for the second quarter of 2025 to be in the range of $95.4 million to $95.5 million
  • Non-GAAP1 gross margin for the second quarter of 2025 to be in the range of 79% to 80%
  • Full year 2025 revenue to be in the range of $365 million to $375 million, compared to prior guidance of $395 million to $405 million

     1Please refer to "Use of Non-GAAP Financial Measure" below for important information about non-GAAP financial measures. Non-     GAAP results exclude share-based compensation.

InMode will host a conference call to discuss the second quarter 2025 financial results on Wednesday, July 30, 2025, at 8:30 a.m. Eastern Time. Speakers will include Moshe Mizrahy, Chief Executive Officer, Yair Malca, Chief Financial Officer and Dr. Michael Kreindel, Chief Technology Officer.

The Company encourages participants to pre-register for the conference call using the following linkhttps://dpregister.com/sreg/10201337/ff895a1432. Callers will receive a unique dial-in upon registration, which enables immediate access on the day of the call. Participants may pre-register at any time, including up to and after the call start time.

For callers that opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

U.S. Toll-Free: 1-833-316-0562
Israel Toll-Free: 1-80-921-2373
International: 1-412-317-5736                                                                                    Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=LXTC7h0D

At:
8:30 a.m. Eastern Time
5:30 a.m. Pacific Time

The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from July 30, 2025, at 12:00 p.m. Eastern Time to August 13, 2025, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers:

Replay U.S. TOLL-FREE: 1-877-344-7529
Replay TOLL/INTERNATIONAL: 1-412-317-0088
Replay Pin Number: 4085483

A replay will also be available for 90 days on InMode's website at: https://inmodemd.com/investors/events-presentations/

About InMode

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

Forward-Looking Statements 

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2025 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 04, 2025, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

Use of Non-GAAP Financial Measures

In addition to InMode's operating results presented in accordance with GAAP, this release includes non-GAAP gross margin. Because this measure is used in InMode's internal analysis of financial and operating performance, management believes that it provides greater transparency to investors of management's view of InMode's economic performance. Management also believes the presentation of this measure, when analyzed in conjunction with InMode's GAAP operating results, allows investors to evaluate and compare the performance of InMode to that of its peers, although InMode's presentation of its non-GAAP measure may not be comparable to other similarly titled measures of other companies more effectively.

Company Contact:

Yair Malca

Chief Financial Officer

Email: Yair.Malca@inmodemd.com

Investor Relations Contact:

Miri Segal

MS-IR LLC

Email: ir@inmodemd.com

Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/inmode-to-report-second-quarter-2025-financial-results-and-hold-conference-call-on-july-30--expects-q2-revenue-between-95-4m-95-5m-decreases-full-year-2025-revenue-guidance-to-be-between-365m-375m-302501437.html

SOURCE InMode Ltd.

FAQ

What is InMode's (INMD) revised revenue guidance for 2025?

InMode has reduced its full-year 2025 revenue guidance to $365-375 million, down from the previous guidance of $395-405 million.

What are InMode's (INMD) expected Q2 2025 financial results?

InMode expects Q2 2025 revenue between $95.4-95.5 million with a non-GAAP gross margin of 79-80%.

Why did InMode (INMD) lower its 2025 revenue guidance?

InMode reduced guidance due to continued market weakness and persistent uncertainty surrounding the U.S. economic outlook.

When will InMode (INMD) report its Q2 2025 earnings?

InMode will report Q2 2025 earnings on July 30, 2025, before the Nasdaq market opens, followed by a conference call at 8:30 a.m. Eastern Time.

What is InMode's (INMD) expected gross margin for Q2 2025?

InMode expects a non-GAAP gross margin between 79% to 80% for Q2 2025.
Inmode Ltd.

NASDAQ:INMD

INMD Rankings

INMD Latest News

INMD Latest SEC Filings

INMD Stock Data

920.96M
53.51M
15.35%
59.24%
5.43%
Medical Devices
Healthcare
Link
Israel
Yokne'am